An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor.


Journal Article

We report a case of Cryptococcus neoformans pneumonia in a patient taking ruxolitinib, a janus kinase 1,2 inhibitor approved for the treatment of myelofibrosis. We hypothesize that ruxolitinib contributed to this infection through its effects on cell-mediated immunity. Clinicians should be aware of the potential for intracellular or opportunistic infections associated with this novel drug class.

Full Text

Cited Authors

  • Wysham, NG; Sullivan, DR; Allada, G

Published Date

  • May 2013

Published In

Volume / Issue

  • 143 / 5

Start / End Page

  • 1478 - 1479

PubMed ID

  • 23648912

Pubmed Central ID

  • 23648912

Electronic International Standard Serial Number (EISSN)

  • 1931-3543

Digital Object Identifier (DOI)

  • 10.1378/chest.12-1604


  • eng

Conference Location

  • United States